Eicosapentaenoic and docosahexaenoic acid derived specialised pro-resolving mediators: Concentrations in humans and the effects of age, sex, disease and increased omega-3 fatty acid intake

doi:10.1016/j.biochi.2020.08.015

Biochimie

Volume 178, November 2020, Pages 105-123

https://doi.org/10.1016/j.biochi.2020.08.015 Get rights and content

Abstract

Although inflammation has a physiological role, unrestrained inflammation can be detrimental, causing tissue damage and disease. Under normal circumstances inflammation is self-limiting with induction of active resolution processes. Central to these is the generation of specialised pro-resolving lipid mediators (SPMs) from eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). These include resolvins, protectins and maresins whose activities have been well described in cell and animal models. A number of SPMs have been reported in plasma or serum in infants, children, healthy adults and individuals with various diseases, as well as in human sputum, saliva, tears, breast milk, urine, synovial fluid and cerebrospinal fluid and in human adipose tissue, skeletal muscle, hippocampus, skin, placenta, lymphoid tissues and atherosclerotic plaques. Differences in SPM concentrations have been reported between health and disease, as would be expected. However, sometimes SPM concentrations are lower in disease and sometimes they are higher. Human studies report that plasma or serum concentrations of some SPMs can be increased by increasing intake of EPA and DHA. However, the relationship of specific intakes of EPA and DHA to enhancement in the appearance of specific SPMs is not clear and needs a more thorough investigation. This is important because of the potential for EPA and DHA to be used more effectively in prevention and treatment of inflammatory conditions. If generation of SPMs represents an important mechanism of action of EPA and DHA, then more needs to be known about the most effective strategies by which EPA and DHA can increase SPM concentrations.

Section snippets

Introduction and scope

Inflammation is a normal part of the immune response. It acts to help in protection against pathogens and is involved in the response to injury and in wound healing [1,2]. The inflammatory response involves many cell types and a plethora of chemical mediators [1,2]. The latter include lipids, peptides, reactive oxygen species, amino acid derivatives and enzymes. The exact mix of chemicals produced depends upon the types of cell involved, the nature of the inflammatory stimulus, where the

EPA and DHA as substrates for synthesis of SPMs

SPMs include resolvins (Rvs), protectins (also known as neuroprotectins) and maresins (MaRs). E- and D-series Rvs are produced from EPA and DHA, respectively, while protectins and MaRs are produced from DHA. SPMs are synthesised using cyclooxygenase (COX) and lipoxygenase (LOX) enzymes often working within the same pathway, outlines of which are provided in Fig. 3, Fig. 4. Synthesis of many SPMs is influenced by aspirin and in the presence and absence of aspirin different epimers of these SPMs,

Blood plasma and serum

Table 1 summarises a number of human studies reporting the concentrations of EPA- and DHA-derived SPMs in plasma or serum [[33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47], [48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63], [64], [65], [66], [67], [68], [69], [70], [71], [72]]. Most studies have used liquid chromatography with tandem mass spectrometry (LC-MS/MS) for analysis although some have used commercial

Effects of sex on EPA and DHA-derived SPMs

Females have higher capacity than males for endogenous synthesis of EPA and DHA from alpha-linolenic acid [92] and a meta-analysis of 51 studies revealed that females have higher plasma concentrations of DHA than males [93]. The higher availability of DHA in females may mean greater capacity to produce D-series Rvs, protectins and maresins than in males. Many studies have reported data on SPM concentrations for mixed groups of males and females (Table 1, Table 2, Table 3) but there are few

Effects of age on EPA and DHA-derived SPMs

The metabolism of n-3 PUFAs (both EPA and DHA) changes with aging [95,96] and there are reports of altered EPA and DHA status in blood, cells and tissues in older compared to younger adults [[97], [98], [99]]. Aging is associated with chronic low-grade inflammation, that predisposes to age-related morbidities [100], suggesting a loss of pro-resolution activity. Despite the many studies reporting data on SPM concentrations in humans (Table 1, Table 2, Table 3), there are few explorations of age

EPA and DHA-derived SPMs in human disease

Many diseases are characterised by chronic inflammation [[1], [2], [3],100]; this may be due, at least in part, to loss to pro-resolution factors. Hence, disease, especially inflammatory disease, might be characterised by lower than usual levels of SPMs. On the other hand, it is possible that on-going inflammation might induce pro-resolving factors to levels that are higher than normal but that they may be ineffective because of an imbalance between pro-inflammatory and pro-resolving mediators

Effects of increased intake of omega-3 fatty acids on SPM concentrations

Since EPA and DHA are precursors for the biosynthesis of SPMs (Fig. 3, Fig. 4), it is self evident that the endogenous production of SPMs is dependent, at least to some extent, upon the availability of EPA and DHA. DHA is usually more abundant than EPA in different body pools in humans, including in blood plasma/serum, leukocytes, erythrocytes, platelets and tissues (see Table 3 of [102]). Increased intake of EPA and DHA results in increased amounts of EPA and DHA in blood lipids, leukocytes,

Summary and discussion

Although inflammation has a physiological role, unrestrained inflammation can be detrimental, causing tissue damage and leading to disease. Therefore, under normal circumstances inflammation is self-limiting with induction of active resolution processes. Central to these is the generation of SPMs from the bioactive n-3 PUFAs EPA and DHA (SPMs are also produced from docosapentaenoic acid). These SPMs include Rvs, protectins and maresins whose activities have been well described in numerous cell

Declaration of competing interest

PCC has received research funding from BASF AS and acts as a consultant to BASF AS, Smartfish, DSM, Cargill and Fresenius-Kabi.

References (106)

C.N. Serhan
Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology
Mol. Aspect. Med.
(2017)
I. Vachier et al.
Endogenous anti-inflammatory mediators from arachidonate in human neutrophils
Biochem. Biophys. Res. Commun.
(2002)
J.K. Innes et al.
Omega-6 fatty acids and inflammation
Prostagl. Leukot. Essent. Fat. Acids
(2018)
G. Bannenberg et al.
Specialized pro-resolving lipid mediators in the inflammatory response: an update
Biochim. Biophys. Acta
(2010)
C.N. Serhan et al.
Resolution phase lipid mediators of inflammation: agonists of resolution
Curr. Opin. Pharmacol.
(2013)
C.N. Serhan et al.
The resolution code of acute inflammation: novel pro-resolving lipid mediators in resolution
Semin. Immunol.
(2015)
K.H. Weylandt
Docosapentaenoic acid derived metabolites and mediators - the new world of lipid mediator medicine in a nutshell
Eur. J. Pharmacol.
(2016)
P.C. Calder
Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance
Biochim. Biophys. Acta Mol. Cell Biol. Lipids
(2015)
L. Balas et al.
An overview of their synthesis and biological significance
Prog. Lipid Res.
(2016)
N. Chiang et al.
Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors
Mol. Aspect. Med.
(2017)

C.N. Serhan et al.

New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration

Mol. Aspect. Med.

(2018)

H. Aoki et al.

Resolvin E1 dampens airway inflammation and hyperresponsiveness in a murine model of asthma

Biochem. Biophys. Res. Commun.

(2008)

S. Bilal et al.

Fat-1 transgenic mice with elevated omega-3 fatty acids are protected from allergic airway responses

Biochim. Biophys. Acta

(2011)

B. Wang et al.

Resolvin D1 protects mice from LPS-induced acute lung injury

Pulm. Pharmacol. Therapeut.

(2011)

A. Barden et al.

Short-term n-3 fatty acid supplementation but not aspirin increases plasma proresolving mediators of inflammation

J. Lipid Res.

(2014)

C. Skarke et al.

Bioactive products formed in humans from fish oils

J. Lipid Res.

(2015)

A.E. Barden et al.

Specialized proresolving lipid mediators in humans with the metabolic syndrome after n-3 fatty acids and aspirin

Am. J. Clin. Nutr.

(2015)

A. Polus et al.

Omega-3 fatty acid supplementation influences the whole blood transcriptome in women with obesity, associated with pro-resolving lipid mediator production

Biochim. Biophys. Acta

(2016)

E. Mas et al.

A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease

Clin. Nutr.

(2016)

V.H.L. See et al.

Effects of postnatal omega-3 fatty acid supplementation on offspring pro-resolving mediators of inflammation at 6 months and 5 years of age: a double blind, randomized controlled clinical trial

Prostagl. Leukot. Essent. Fat. Acids

(2017)

H.A. Bazan et al.

Circulating inflammation-resolving lipid mediators RvD1 and DHA are decreased in patients with acutely symptomatic carotid disease

Prostagl. Leukot. Essent. Fat. Acids

(2017)

A. Barden et al.

The effects of alcohol on plasma lipid mediators of inflammation resolution in patients with Type 2 diabetes mellitus

Prostagl. Leukot. Essent. Fat. Acids

(2018)

A.V. Sorokin et al.

Identification of proresolving and inflammatory lipid mediators in human psoriasis

J. Clin. Lipidol.

(2018)

A. Barden et al.

Antiemetic doses of dexamethasone and their effects on immune cell populations and plasma mediators of inflammation resolution in healthy volunteers

Prostagl. Leukot. Essent. Fat. Acids

(2018)

A. Toewe et al.

Simultaneous determination of PUFA-derived pro-resolving metabolites and pathway markers using chiral chromatography and tandem mass spectrometry

Anal. Chim. Acta

(2018)

J.L. Ramirez et al.

Fish oil increases specialized pro-resolving lipid mediators in PAD (The OMEGA-PAD II Trial)

J. Surg. Res.

(2019)

L.E. Fosshaug et al.

Early increase of specialized pro-resolving lipid mediators in patients with ST-elevation myocardial infarction

EBioMed

(2019)

N. Morshedzadeh et al.

Resolvin D1 impacts on insulin resistance in women with polycystic ovary syndrome and healthy women

Diabetes Metab. Syndr.

(2019)

J. Yang et al.

Metabolomic profiling of regulatory lipid mediators in sputum from adult cystic fibrosis patients

Free Radic. Biol. Med.

(2012)

J.T. English et al.

Identification and profiling of specialized pro-resolving mediators in human tears by lipid mediator metabolomics

Prostagl. Leukot. Essent. Fat. Acids

(2017)

H. Arnardottir et al.

Human milk proresolving mediators stimulate resolution of acute inflammation

Mucosal Immunol.

(2016)

M. Giera et al.

Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by means of LC-MS/MS

Biochim. Biophys. Acta

(2012)

X. Wang et al.

Resolution of inflammation in neuromyelitis optica spectrum disorders

Mult. Scler. Relat. Disord.

(2019)

T. Yang et al.

Maresin 1 attenuates neuroinflammation in a mouse model of perioperative neurocognitive disorders

Br. J. Anaesth.

(2019)

E.J. Baker et al.

Metabolism and functional effects of plant-derived omega-3 fatty acids in humans

Prog. Lipid Res.

(2016)

M. Plourde et al.

Kinetics of 13C-DHA before and during fish-oil supplementation in healthy older individuals

Am. J. Clin. Nutr.

(2014)

P. Léveillé et al.

Metabolism of uniformly labeled 13C-eicosapentaenoic acid and 13C-arachidonic acid in young and old men

Am. J. Clin. Nutr.

(2017)

D. Rees et al.

Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men

Am. J. Clin. Nutr.

(2006)

P.C. Calder et al.

Health relevance of the modification of low grade inflammation in ageing (inflammageing) and the role of nutrition

Ageing Res. Rev.

(2017)

P.C. Calder et al.

Inflammatory disease processes and interactions with nutrition

Br. J. Nutr.

(2009)

P.C. Calder et al.

A consideration of biomarkers to be used for evaluation of inflammation in human nutritional studies

Br. J. Nutr.

(2013)

C. Barnig et al.

Activation of resolution pathways to prevent and fight chronic inflammation: lessons from asthma and inflammatory bowel disease

Front. Immunol.

(2019)

B.D. Levy et al.

Lipid mediator class switching during acute inflammation: signals in resolution

Nat. Immunol.

(2001)

P.C. Calder

Omega-3 (n-3) polyunsaturated fatty acids and inflammation: from membrane to nucleus and from bench to bedside

Proc. Nutr. Soc.

(2020)

P.C. Calder

Omega-3 fatty acids and inflammatory processes: from molecules to man

Biochem. Soc. Trans.

(2017)

C.N. Serhan et al.

Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators

J. Clin. Invest.

(2018)

N. Chiang et al.

The specialised pro-resolving mediator network: an update on in vivo production and actions

Essays Biochem.

(2020)

J. Dalli et al.

Maresin conjugates in tissue regeneration biosynthesis enzymes in human macrophages

Proc. Natl. Acad. Sci. U.S.A.

(2016)

J.F. Lima-Garcia et al.

The precursor of resolvin D series and aspirin-triggered resolvin D1 display anti-hyperalgesic properties in adjuvant-induced arthritis in rats

Br. J. Pharmacol.

(2011)

H.A. Benabdoun et al.

In vitro and in vivo assessment of the proresolutive and antiresorptive actions of resolvin D1: relevance to arthritis

Arthritis Res. Ther.

(2019)

Cited by (80)

New evidence for efficacy of marine-sourced n-3 fatty acids in postoperative patients
2024, American Journal of Clinical Nutrition
Lipids and lipid signaling molecules in human milk and infant formula, a chemical characterization of relevant biochemical components
2024, Journal of Nutritional Biochemistry
Breastfeeding is the gold standard in infant nutrition and continuous researches aim to optimize infant formula composition as the best alternative available. Human milk lipid content provides more than 50% of energy requirements for infants together with essential vitamins, polyunsaturated fatty acids, and other bioactive components. While fatty acids and vitamins human milk content has been extensively studied and, when needed those have been added to infant formulas, less is known about polyunsaturated fatty acids functional derivatives and other bioactive components. Here we describe the comparison of lipid compositions in breast milk from 22 healthy volunteers breastfeeding mothers and the six most common infant formula devoting particular attention to two families of signaling lipids, endocannabinoids, and eicosanoids. The main differences between breast milk and formulas lie in a variety of saturated fatty and unsaturated fatty acids, in the total amount (45–95% less in infant formula) and a variety of endocannabinoids and eicosanoids (2-AG, 5(s)HETE, 15(S)-HETE and 14,15-EET).
APOEε4 genotype and DHA and EPA supplementation on the outcomes of cognitive decline: A systematic review of randomized clinical trials
2024, Human Nutrition and Metabolism
Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) supplementation has been used to improve cognitive outcomes in diseases associated with cognition. However, the influence of APOEε4 genotype on these relationships remains unclear. Therefore, this systematic review aims to discuss the evidence regarding the effects of DHA and EPA supplementation on cognitive decline variables and relate them to APOEε4 genotype in middle-aged and older adults. The Medline (via PubMed), Scopus, Web of Science, and Bireme/Lilacs databases were searched for studies, retrieving 1863 articles. After the step selection, two randomized clinical trials (RCTs) that evaluated the effects of EPA and DHA supplementation on cognitive variables were included. All the methodological steps were performed by two raters. The results of the RCTs were not congruent, as the non-carriers in the APOEε4 supplemented group performed worse in the quick-choice reaction time cognitive domain, whereas the carriers improved in the reasoning domain. The increase in DHA concentration in the supplemented group was lower in APOEε4 carriers than in individuals with other genotypes. Additionally, a smaller decline in right hippocampal brain volume correlated with higher EPA concentrations after supplementation in APOEε4 non-carriers. The dosage and supplementation time (18 months) were similar between studies. In conclusion, DHA and EPA supplementation showed no pragmatic effects on cognitive variables when considering the presence of the APOEε4 allele.
Effects of APOE4 on omega-3 brain metabolism across the lifespan
2024, Trends in Endocrinology and Metabolism
Omega-3 (n-3) polyunsaturated fatty acids (PUFAs), such as docosahexaenoic acid (DHA), have important roles in human nutrition and brain health by promoting neuronal functions, maintaining inflammatory homeostasis, and providing structural integrity. As Alzheimer’s disease (AD) pathology progresses, DHA metabolism in the brain becomes dysregulated, the timing and extent of which may be influenced by the apolipoprotein E ε4 (APOE4) allele. Here, we discuss how maintaining adequate DHA intake early in life may slow the progression to AD dementia in cognitively normal individuals with APOE4, how recent advances in DHA brain imaging could offer insights leading to more personalized preventive strategies, and how alternative strategies targeting PUFA metabolism pathways may be more effective in mitigating disease progression in patients with existing AD dementia.
Prolonged experimental sleep disturbance affects the inflammatory resolution pathways in healthy humans
2023, Brain, Behavior, and Immunity
Sleep disturbances, as manifested in insomnia symptoms of difficulties falling asleep or frequent nighttime awakenings, are a strong risk factor for a diverse range of diseases involving immunopathology. Low-grade systemic inflammation has been frequently found associated with sleep disturbances and may mechanistically contribute to increased disease risk. Effects of sleep disturbances on inflammation have been observed to be long lasting and remain after recovery sleep has been obtained, suggesting that sleep disturbances may not only affect inflammatory mediators, but also the so-called specialized pro-resolving mediators (SPMs) that actively resolve inflammation. The goal of this investigation was to test for the first time whether the omega-3 fatty acid-derived D- (RvD) and E-series (RvE) resolvins are impacted by prolonged experimental sleep disturbance (ESD).
Twenty-four healthy participants (12 F, age 20–42 years) underwent two 19-day in-hospital protocols (ESD/control), separated by > 2 months. The ESD protocol consisted of repeated nights of short and disrupted sleep with intermittent nights of undisturbed sleep, followed by three nights of recovery sleep at the end of the protocol. Under the control sleep condition, participants had an undisturbed sleep opportunity of 8 h/night throughout the protocol. The D- and E-series resolvins were measured in plasma using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
The precursor of the D-series resolvins, 17-HDHA, was downregulated in the ESD compared to the control sleep condition (p <.001 for condition), and this effect remained after the third night of recovery sleep has been obtained. This effect was also observed for the resolvins RvD3, RvD4, and RvD5 (p <.001 for condition), while RvD1 was higher in the ESD compared to the control sleep condition (p <.01 for condition) and RvD2 showed a mixed effect of a decrease during disturbed sleep followed by an increase during recovery sleep in the ESD condition (p <.001 for condition*day interaction). The precursor of E-series resolvins, 18-HEPE, was downregulated in the ESD compared to the control sleep condition (p <.01 for condition) and remained low after recovery sleep has been obtained. This effect of downregulation was also observed for RvE2 (p <.01 for condition), while there was no effect for RvE1 (p >.05 for condition or condition*day interaction). Sex-differential effects were found for two of the D-series resolvins, i.e., RvD2 and RvD4.
This first investigation on the effects of experimental sleep disturbance on inflammatory resolution processes shows that SPMs, particularly resolvins of the D-series, are profoundly downregulated by sleep disturbances and remain downregulated after recovery sleep has been obtained, suggesting a longer lasting impact of sleep disturbances on these mediators. These findings also suggest that sleep disturbances contribute to the development and progression of a wide range of diseases characterized by immunopathology by interfering with processes that actively resolve inflammation. Pharmacological interventions aimed at promoting inflammatory resolution physiology may help to prevent future disease risk as a common consequence of sleep disturbances. Trial Registration: ClinicalTrials.gov NCT02484742.
Formation of lipoxins and resolvins in human leukocytes
2023, Prostaglandins and Other Lipid Mediators
Specialized pro-resolving lipid mediators (SPMs) such as lipoxins or resolvins are formed by the consecutive action of 5-lipoxygenase (5-LO, ALOX5) and different types of arachidonic acid 12- or 15-lipoxygenases using arachidonic acid, eicosapentaenoic acid or docosahexaenoic acid as substrate. Lipoxins are trihydroxylated oxylipins which are formed from arachidonic and eicosapentaenoic acid. The latter can also be converted to di- and trihydroxylated resolvins of the E series, whereas docosahexaenoic acid is the substrate for the formation of di- and trihydroxylated resolvins of the D series. Here, we summarize the formation of lipoxins and resolvins in leukocytes. From the data published so far, it becomes evident that FLAP is required for the biosynthesis of most of the lipoxins and resolvins. Even in the presence of FLAP, formation of the trihydroxylated SPMs (lipoxins, RvD1-RvD4, RvE1) in leukocytes is very low or undetectable which is obviously due to the extremely low epoxide formation by 5-LO from oxylipins such as 15-H(p)ETE, 18-H(p)EPE or 17-H(p)DHA. As a result, only the dihydroxylated oxylipins (5 S,15S-diHETE, 5 S,15S-diHEPE) and resolvins (RvD5, RvE2, RvE4) can be consistently detected using leukocytes as SPM source. However, the reported levels of these dihydroxylated lipid mediators are still much lower than those of the typical pro-inflammatory mediators including the monohydroxylated fatty acid derivatives (e.g. 5-HETE), leukotrienes or cyclooxygenase-derived prostaglandins. Since 5-LO expression is mainly restricted to leukocytes these cells are considered as the main source of SPMs. The low formation of trihydroxylated SPMs in leukocytes, the fact that they are hardly detected in biological samples as well as the lack of functional signaling by their receptors make it highly questionable that trihydroxylated SPMs play a role as endogenous mediators in the resolution of inflammation.

View all citing articles on Scopus

View full text

Eicosapentaenoic and docosahexaenoic acid derived specialised pro-resolving mediators: Concentrations in humans and the effects of age, sex, disease and increased omega-3 fatty acid intake

Abstract

Section snippets

Introduction and scope

EPA and DHA as substrates for synthesis of SPMs

Blood plasma and serum

Effects of sex on EPA and DHA-derived SPMs

Effects of age on EPA and DHA-derived SPMs

EPA and DHA-derived SPMs in human disease

Effects of increased intake of omega-3 fatty acids on SPM concentrations

Summary and discussion

Declaration of competing interest

Mol. Aspect. Med.

Biochem. Biophys. Res. Commun.

Prostagl. Leukot. Essent. Fat. Acids

Biochim. Biophys. Acta

Curr. Opin. Pharmacol.

Semin. Immunol.

Eur. J. Pharmacol.

Biochim. Biophys. Acta Mol. Cell Biol. Lipids

Prog. Lipid Res.

Mol. Aspect. Med.

Mol. Aspect. Med.

Biochem. Biophys. Res. Commun.

Biochim. Biophys. Acta

Pulm. Pharmacol. Therapeut.

J. Lipid Res.

J. Lipid Res.

Am. J. Clin. Nutr.

Biochim. Biophys. Acta

Clin. Nutr.

Prostagl. Leukot. Essent. Fat. Acids

Prostagl. Leukot. Essent. Fat. Acids

Prostagl. Leukot. Essent. Fat. Acids

J. Clin. Lipidol.

Prostagl. Leukot. Essent. Fat. Acids

Anal. Chim. Acta

J. Surg. Res.

EBioMed

Diabetes Metab. Syndr.

Free Radic. Biol. Med.

Prostagl. Leukot. Essent. Fat. Acids

Mucosal Immunol.

Biochim. Biophys. Acta

Mult. Scler. Relat. Disord.

Br. J. Anaesth.

Prog. Lipid Res.

Am. J. Clin. Nutr.

Am. J. Clin. Nutr.

Am. J. Clin. Nutr.

Ageing Res. Rev.

Inflammatory disease processes and interactions with nutrition

Br. J. Nutr.

A consideration of biomarkers to be used for evaluation of inflammation in human nutritional studies

Br. J. Nutr.

Activation of resolution pathways to prevent and fight chronic inflammation: lessons from asthma and inflammatory bowel disease

Front. Immunol.

Lipid mediator class switching during acute inflammation: signals in resolution

Nat. Immunol.

Omega-3 (n-3) polyunsaturated fatty acids and inflammation: from membrane to nucleus and from bench to bedside

Proc. Nutr. Soc.

Omega-3 fatty acids and inflammatory processes: from molecules to man

Biochem. Soc. Trans.

Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators

J. Clin. Invest.

The specialised pro-resolving mediator network: an update on in vivo production and actions

Essays Biochem.

Maresin conjugates in tissue regeneration biosynthesis enzymes in human macrophages

Proc. Natl. Acad. Sci. U.S.A.

The precursor of resolvin D series and aspirin-triggered resolvin D1 display anti-hyperalgesic properties in adjuvant-induced arthritis in rats

Br. J. Pharmacol.

In vitro and in vivo assessment of the proresolutive and antiresorptive actions of resolvin D1: relevance to arthritis

Arthritis Res. Ther.